BridgeBio Pharma Inc

NASDAQ:BBIO 4:00:00 PM EDT

12.84

-0.62 (-4.61%)

7:53:54 PM EDT: $12.81 -0.03 (-0.23%)

Products

BridgeBio Pharma, Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma

Published: 12/01/2020 12:48 GMT

BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma and Affiliate Qed Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma.
Bridgebio Pharma Inc - New Drug Application (nda) for Infigratinib Granted Priority Review Designation.